BiomX Inc
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
HLSQ$0.07-37.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| For the Six Months Ended June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| CASH FLOWS – OPERATING ACTIVITIES | ||
| Net loss | (12,856) | (12,772) |
| Adjustments required to reconcile cash flows used in operating activities: | ||
| Depreciation and amortization | 560 | 440 |
| Stock-based compensation | 254 | 446 |
| Amortization of debt issuance costs | - | 331 |
| Finance income, net | (506) | (180) |
| Revaluation of contingent consideration | (2) | 2 |
| Income from change in fair value of Private Placement Warrants | (3,858) | - |
| Private Placement Warrants issuance cost | 732 | - |
| Change in contract liability | (1,976) | - |
| Loss from sale of fixed assets, net | 97 | - |
| Changes in operating assets and liabilities: | ||
| Other current and non-current assets | 803 | 59 |
| Trade accounts payable | (2,229) | 1,353 |
| Other accounts payable | (2,921) | 1,238 |
| Net change in operating leases | (691) | (39) |
| Net cash used in operating activities | (22,593) | (9,122) |
| CASH FLOWS – INVESTING ACTIVITIES | ||
| Cash and Restricted Cash acquired from the APT acquisition | 663 | - |
| Proceeds from short-term deposits | - | 2,000 |
| Proceeds from sale of fixed assets | 63 | - |
| Purchases of property and equipment | (9) | (11) |
| Net cash provided by investing activities | 717 | 1,989 |
| CASH FLOWS – FINANCING ACTIVITIES | ||
| Issuance of Private Placement Warrants under March 2024 PIPE | 28,745 | - |
| Issuance of Redeemable Convertible Preferred Shares under March 2024 PIPE | 21,269 | - |
| March 2024 PIPE issuance costs | (507) | - |
| Issuance costs from February 2023 PIPE | - | (301) |
| Issuance of Common Stock and Warrants under February 2023 PIPE | - | 7,485 |
| Pre-Funded Warrants exercise | 6 | - |
| Issuance of Common Stock under Open Market Sales Agreement, net of issuance costs | 19 | - |
| Issuance cost from the APT acquisition | (13) | - |
| Repayment of long-term debt | (10,747) | (1,654) |
| Net cash provided by financing activities | 38,772 | 5,530 |
| Increase (decrease) in cash and cash equivalents and restricted cash | 16,896 | (1,603) |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | (46) | (29) |
| Cash and cash equivalents and restricted cash at the beginning of the period | 15,864 | 32,294 |
| Cash and cash equivalents and restricted cash at the end of the period | 32,714 | 30,662 |
| RECONCILIATION OF AMOUNTS ON CONSOLIDATED BALANCE SHEETS | ||
| Cash and cash equivalents | 31,611 | 29,711 |
| Restricted cash | 1,103 | 951 |
| Total cash and cash equivalents and restricted cash | 32,714 | 30,662 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||
| Cash paid for interest | 1,419 | 992 |
| Taxes paid | 7 | 14 |
| SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||
| Issuance costs from February 2023 PIPE included in trade accounts payable | - | 32 |
| Property and equipment purchases included in accounts payable and Trade payable | 10 | 29 |
| Issuance cost from March 2024 PIPE | 1,685 | - |
| Issuance cost from the APT acquisition | 38 | - |
| Issuance of Common Stock under the APT acquisition | 3,041 | - |
| Issuance of Redeemable Convertible Preferred Shares under the APT acquisition | 12,610 | - |
| Issuance of Merger Warrants under the APT acquisition | 200 | - |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.